AstraZeneca (LON:AZN) Hits New 52-Week High at $12,488.00

AstraZeneca PLC (LON:AZN)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as £124.88 ($154.25) and last traded at £121.42 ($149.98), with a volume of 70283445 shares. The stock had previously closed at £119.88 ($148.07).

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Berenberg Bank reissued a “buy” rating on shares of AstraZeneca in a research note on Wednesday, March 13th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Monday, April 15th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, April 4th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £105 ($129.69) price target on shares of AstraZeneca in a research report on Tuesday, April 23rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a £110 ($135.87) price target on shares of AstraZeneca in a research report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of £116.86 ($144.34).

AstraZeneca Stock Up 0.8 %

The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. The stock has a 50-day simple moving average of £105.78 and a 200-day simple moving average of £104.45. The firm has a market capitalization of £187.21 billion, a PE ratio of 3,956.44, a P/E/G ratio of 0.89 and a beta of 0.19.

AstraZeneca Increases Dividend

The company also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a GBX 156 ($1.93) dividend. This is an increase from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is currently 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.